Roblin X, Moschetti E, Barrau M, Cheifetz AS, et al. Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2024 May 3:S1542-3565(24)00402.
PMID: 38705437